NCNA - ニュ―カナ （NuCana plc）

NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer…

Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ann…

Near Intelligence (NASDAQ: NIR ) stock is on the move Monday as the company’s shares continue to fluctuate following its public debut . Near Intelligence went public last week when it combined with special purpose acquisition company (SPAC) Kludein I Acquisition. The merger was completed on Thursday with shares of the company’s stock starting to trade on Friday. During its first day of trading, shares of NIR stock rose roughly 12%. However, today’s movement has the company more than giving up the gains it made during its public debut. It’s worth noting investors often see volatility in a stock shortly after it goes public. In the case of NIR stock, it’s taking a 17.3% beating as of Monday morning. That comes alongside some 20,000 shares changing hands. That’s not much compared to its prior daily trading volume of around 77,000 shares. What Is Near Intelligence? Near Intelligence is a data intelligence company focused on its software-as-a-service (SaaS) platform. This has it offering up information on consumers to companies to help them better curate customer experiences.

NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company’s European Patent 2955190 isn’t valid. This follows up a similar ruling last week that invalidated the patent in the U.K. Hugh Griffith, founder and CEO of NuCana, said the following about the TBA’s decision. “While we are disappointed by these decisions, they do not impact our core business of developing innovative new medicines for the treatment of patients with cancer. NuCana is well-capitalized, all of our clinical programs remain on track and we expect multiple data announcements in 2023.” How This Affects NCNA Stock Investors in NCNA stock aren’t reacting well to the patent news. As a result, the company’s stock is seeing heavy trading as shareholders sell the stock. For the record, that has some 200,000 shares trading hands as of this writing.

Ruling Has No Impact on NuCana''s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the …

Near Intelligence (NASDAQ: NIR ) stock is on the move Monday as the company’s shares continue to fluctuate following its public debut . Near Intelligence went public last week when it combined with special purpose acquisition company (SPAC) Kludein I Acquisition. The merger was completed on Thursday with shares of the company’s stock starting to trade on Friday. During its first day of trading, shares of NIR stock rose roughly 12%. However, today’s movement has the company more than giving up the gains it made during its public debut. It’s worth noting investors often see volatility in a stock shortly after it goes public. In the case of NIR stock, it’s taking a 17.3% beating as of Monday morning. That comes alongside some 20,000 shares changing hands. That’s not much compared to its prior daily trading volume of around 77,000 shares. What Is Near Intelligence? Near Intelligence is a data intelligence company focused on its software-as-a-service (SaaS) platform. This has it offering up information on consumers to companies to help them better curate customer experiences.

NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company’s European Patent 2955190 isn’t valid. This follows up a similar ruling last week that invalidated the patent in the U.K. Hugh Griffith, founder and CEO of NuCana, said the following about the TBA’s decision. “While we are disappointed by these decisions, they do not impact our core business of developing innovative new medicines for the treatment of patients with cancer. NuCana is well-capitalized, all of our clinical programs remain on track and we expect multiple data announcements in 2023.” How This Affects NCNA Stock Investors in NCNA stock aren’t reacting well to the patent news. As a result, the company’s stock is seeing heavy trading as shareholders sell the stock. For the record, that has some 200,000 shares trading hands as of this writing.

Ruling Has No Impact on NuCana''s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the …

NuCana’s market cap is not reflecting potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. See why I rate NCNA stock a strong buy.

EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC …

NuCana’s market cap is not reflecting potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. See why I rate NCNA stock a strong buy.

EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC …

NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination…

At current trading levels, NCNA seems to be a speculative but compelling SOTP story. It would seem to merit a small "watch item" position in diversified biotech portfolio. Read more here.

NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in P…